Skip to main content
. 2020 Nov 7;489:112909. doi: 10.1016/j.jim.2020.112909

Table 1A.

Positivity for anti-SARS-CoV-2 IgM and IgG by Biolidics in patients with SARS-CoV-2a

Total, n Positive, n Sensitivity (%) 95% CI
D0 IgM+ 24 7 29% 13–51%
IgG+ 24 5 21% 7–42%
IgG+ or IgM+ 24 7 29% 13–51%
D7 IgM+ 26 14 54% 33–73%
IgG+ 26 23 88% 70–98%
IgG+ or IgM+ 26 24 92% 75–99%
a

D0, day 0 after PCR diagnosis; D7, day 7 after PCR diagnosis; 95% CI, 95% confidence interval.